Physician profile
Drew A Smith
NPI 1083682991
$3,414.41
in general payments reported to CMS, 2019-2025
29 companies · $352 in 2025
The $352 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,857 · 2020: $394 · 2021: $15.82 · 2023: $282 · 2024: $513 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,147.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irras USA, INC. | $936.09 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $391.06 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $228.76 | 2023-2025 | Vraylar, Ubrelvy |
| Sunovion Pharmaceuticals INC. | $179.02 | 2019-2020 | |
| Amgen INC. | $159.27 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $152.13 | 2023-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $137.38 | 2019-2025 | Capvaxive, Gardasil 9, Vaxelis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.77 | 2019-2025 | |
| Novo Nordisk INC | $118.84 | 2019-2024 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $103.92 | 2019-2020 | |
| Pfizer INC. | $97.77 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $75.24 | 2025 | Caplyta |
| Exact Sciences Corporation | $75.13 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $67.43 | 2019-2020 | |
| Allergan, INC. | $61.94 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $55.74 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $54.61 | 2019 | |
| Novartis Pharmaceuticals Corporation | $53.34 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $41.10 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $40.59 | 2019 | |
| Dexcom, INC. | $40.37 | 2023-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $37.86 | 2023-2024 | Freestyle Libre |
| Vifor Pharma, INC. | $32.93 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.43 | 2024 | |
| Organon LLC | $30.46 | 2023-2024 | Nexplanon |
| Mylan Specialty L.P. | $26.60 | 2019 | |
| Bioventus LLC | $24.10 | 2019 | |
| Phathom Pharmaceuticals, INC. | $14.98 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.